Recombinant Vaccines Market: By Type (Subunit and Live Attenuated), By Route of Administration (Parenteral and Oral), By Disease Indication (Human Papillomavirus, Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, and Others) By Distribution Channel (Hospitals & Retail Pharmacies, Government Suppliers, and Others) and Geography

Recombinant Vaccines Market was estimated to be valued at USD 11,507.3 million in 2022, and it is expanded to grow at a significant CAGR of 5.3% over 2023-2029. The main factors driving the global recombinant vaccine market are the full-fledged recombinant properties in providing the effectiveness and safety of the patient getting immunized. Additionally, the increasing prevalence of viral diseases in countries worldwide is anticipated to boost the market. The growing population and strict regulations for infant immunization are projected to drive the overall market. Another significant driving force is the improvement of technology in the fields of recombinant DNA technology, genetics, and proteomics, which is boosting vaccination R&D. As a result, the number of clinical trials is increasing. Based on the Route of Administration, the parenteral segment has a significant share of the global recombinant vaccines market with a share of 87.3% in 2022 the global market and is projected to grow at 4.9% CAGR from 2023 - 2029. The parenteral vaccines, such as enhanced potency inactivated polio vaccine, Haemophilus influenzae type B, hepatitis B virus (HBV), and other non-mucosal vaccines, have been highly effective in preventing systemic disease during subsequent exposure to natural infection.

Recent Market Developments:

• In Jan 2021, Merck, a leading science and technology company, announced the acquisition of Amptek, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens Merck's capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments, and diagnostics applicable in Covid-19 and many other diseases. Financial terms were not disclosed.
• In April 2021, Sanofi and GSK announce that they have signed a letter of intent to enter collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.